The life sciences technology company will be able to offer services to the pharmacies associated with Legacy.
PrimeRx announced that it has formed a partnership with Legacy Pharmacy Group, a group purchasing organization for independent pharmacies in the New York region.1 This will provide PrimeRx, a pharmacy management software provider, with access to the more than 550 pharmacies in Legacy’s network.
In a press release, PrimeRx’s CEO Ketan Mehta said, “We are pleased to partner with the highly respected Legacy Pharmacy Group, which has a well-earned reputation for helping independent pharmacies operate at the highest levels of efficiency. Legacy pharmacies are committed to managing costs and protecting their bottom lines. PrimeRx is a natural fit for efficiency-focused pharmacies, and we look forward to introducing the system to network members.”
Legacy’s CEO Ritesh Shah also said, “This brings tremendous value to our GPO, our members will benefit from PrimeRx partnership.”
In July, PrimeRx launched PrimeRX MARKET, an online marketplace for pharmacies designed to provide competitive inventory options.2
In a press release, Mehta said, “We are thrilled to introduce PrimeRx MARKET to our solutions portfolio. PrimeRx has a strong track record of simplifying complex challenges. The drug procurement process for pharmacies, a major expense, requires precise contract compliance and inventory management to maintain cash flow and profitability. PrimeRx MARKET empowers pharmacies to source drugs intelligently and conveniently by integrating purchase and dispensing data, ensuring compliance and market agility. Our goal is to use data intelligence to streamline purchasing decisions, enabling pharmacies to remain profitable and dedicated to serving their patients."
Earlier, in June, PrimeRx announced the launch its PrimeRx Cloud technology solution, a digital platform designed specifically for independent pharmacies.3
At the time, Mehta said, “PrimeRx Cloud is the next step in pharmacy technology. We are proud to offer this addition to the PrimeRx product portfolio, which addresses the need for users to have flexibility in where, when, and how they manage their pharmacies."
In the same press release, PrimeRx’s chief technology officer Darrell Hyde said, “PrimeRx Cloud solves a number of serious problems facing today's busy pharmacies, including the need for increased flexibility and reduced IT overhead and risk. Pharmacy management no longer takes place just behind the pharmacy counter. Today's pharmacy owners are checking in from home, often long after the pharmacy has closed for the day. PrimeRx Cloud enables the modern owner to operate from anywhere while also removing the need to operate complex IT infrastructure in the pharmacy."
The company’s chief sales and marketing officer Tillmann Schwabe also said, “PrimeRx Cloud supports our goal of helping pharmacists build healthier communities. Our browser-based solution makes it easier for pharmacists to serve their patients, namely by reducing the administrative workload, which allows more time for in-person interactions."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.